Personalis Announces Launch of Public Offering of Common Stock
12 8월 2020 - 5:26AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for population sequencing and cancer, today announced that it has
commenced an underwritten public offering of $100 million of its
common stock. In addition, Personalis expects the underwriters to
be granted a 30-day option to purchase up to an additional $15
million of common stock from a selling stockholder on the same
terms and conditions. Personalis will not receive any proceeds from
any sale of shares by the selling stockholder.
The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering may be completed or
as to the actual size or terms of the offering.
BofA Securities, Citigroup and Cowen are acting as joint
book-running managers. BTIG, Needham & Company and Oppenheimer
& Co. are acting as co-managers.
A shelf registration statement relating to the shares being sold
in this offering was filed with the U.S. Securities and Exchange
Commission on July 2, 2020, and was declared effective on July 10,
2020. The offering will be made only by means of a prospectus
supplement and accompanying prospectus. A preliminary prospectus
supplement and accompanying prospectus relating to the offering
have been filed with the SEC and are available for free on the
SEC’s website located at http://www.sec.gov. When available,
electronic copies of the preliminary prospectus supplement and
accompanying prospectus relating to the proposed public offering
may be obtained from BofA Securities, Inc., Attention: Prospectus
Department, NC1‐004‐03‐43, 200 North College Street, 3rd floor,
Charlotte, NC 28255‐0001, or by emailing
dg.prospectus_requests@baml.com; Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at 1-800-831-9146; or Cowen and Company,
LLC, c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, New York 11717,
telephone: 631‐274‐2806.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Personalis, Inc.
Personalis, Inc. is a growing population sequencing and cancer
genomics company, with a continuing focus on scale, efficiency and
quality. In oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The company’s
ImmunoID NeXT Platform® is designed to adapt to the complex and
evolving understanding of cancer, providing its biopharmaceutical
customers with information on all of the approximately 20,000 human
genes, together with the immune system, from a single tissue
sample. The Personalis® Clinical Laboratory is GxP aligned as well
as CLIA’88-certified and CAP-accredited.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements relating to Personalis’ expectations regarding
the proposed public offering. These statements are subject to
significant risks and uncertainties and actual results could differ
materially from those projected. Personalis cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions,
the risk that the proposed public offering will not be consummated
on the terms or in the amounts contemplated or otherwise, and the
satisfaction of customary closing conditions related to the
proposed public offering. Risks and uncertainties relating to
Personalis and its business can be found in the “Risk Factors”
section of Personalis’ Form 10-Q for the quarter ended June 30,
2020, filed with the SEC on August 6, 2020, and in the preliminary
prospectus supplement related to the proposed public offering filed
with the SEC on August 11, 2020. Personalis undertakes no duty or
obligation to update any forward-looking statements contained in
this release as a result of new information, future events or
changes in Personalis’ expectations, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200811005819/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com
415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024